• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Gland Share Price

    Gland Pharma Share PriceGland Pharma

    Large Cap 14.4k Result
    ₹1,792.9
    15.15 (0.85%)
    • Advice
    • Hold
    As on 11 December, 2023 | 12:22 BSE: 543245 NSE: GLANDISIN: INE068V01023

    Gland Pharma Performance

    Day Range

    • Low 1,756.55
    • High 1,797.85
    ₹ 1,792.9

    52 Week Range

    • Low 861.00
    • High 1,841.80
    ₹ 1,792.9
    • Open Price1,779.95
    • Previous Close1,777.75
    • Volume65939

    Start SIP in Gland Pharma

    Start SIP

    Gland Pharma Share Price

    • Over 1 Month 10.32%
    • Over 3 Month 5.94%
    • Over 6 Month 88.36%
    • Over 1 Year 4.51%

    Gland Pharma Key Statistics

    P/E Ratio 42.3
    PEG Ratio -1.3
    Market Cap Cr 29,529
    Price to Book Ratio 3.7
    EPS 49.5
    Dividend 0
    Relative Strength Index 63.63
    Money Flow Index 77.52
    MACD Signal 45.59
    Average True Range 53.84

    Gland Pharma Investment Rating

    • Master Rating:

    • Gland Pharma has an operating revenue of Rs. 4,305.42 Cr. on a trailing 12-month basis. An annual revenue de-growth of -16% needs improvement, Pre-tax margin of 29% is great, ROE of 9% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 28% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -1% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 64 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Gland Pharma Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,0118847859261,0488571,103
    Operating Expenses Qtr Cr 664625616642753587755
    Operating Profit Qtr Cr 347259169284295270348
    Depreciation Qtr Cr 40393838373531
    Interest Qtr Cr 1223212
    Tax Qtr Cr 90663378837995
    Net Profit Qtr Cr 25818879228240229286
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 3,8574,625
    Operating Expenses Annual Cr 2,5982,890
    Operating Profit Annual in Cr 1,0191,511
    Depreciation Cr 147110
    Interest Annual Cr 75
    Tax Annual Cr 273407
    Net Profit Annual Cr 7761,212
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 368791
    Cash from Investing Activity Annual Cr 1,208-1,010
    Cash from Financing Annual Activity Cr 1535
    Net Cash Flow Annual Cr 1,591-184
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 7,9537,158
    Fixed Assets Annual Cr 1,7481,693
    Total Non Current Assets Annual Cr 1,8851,990
    Total Current Assets Annual Cr 6,8885,844
    Total Assets Annual Cr 8,7737,834
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 483436
    ROE Annual % 1017
    ROCE Annual % 1422
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3539
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,3731,2097859381,0448571,103
    Operating Expenses Qtr Cr 1,049915617649748587755
    Operating Profit Qtr Cr 324294168290297270348
    Depreciation Qtr Cr 81653838373531
    Interest Qtr Cr 6523212
    Tax Qtr Cr 96673279837995
    Net Profit Qtr Cr 19419479232241229286
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 3,8654,625
    Operating Expenses Annual Cr 2,6002,891
    Operating Profit Annual in Cr 1,0251,510
    Depreciation Cr 147110
    Interest Annual Cr 75
    Tax Annual Cr 274407
    Net Profit Annual Cr 7811,212
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 364791
    Cash from Investing Activity Annual Cr 1,208-1,003
    Cash from Financing Annual Activity Cr 1535
    Net Cash Flow Annual Cr 1,587-177
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 7,9597,158
    Fixed Assets Annual Cr 1,7481,693
    Total Non Current Assets Annual Cr 1,8771,982
    Total Current Assets Annual Cr 6,9015,852
    Total Assets Annual Cr 8,7787,834
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 483436
    ROE Annual % 1017
    ROCE Annual % 1422
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3539
    Invest in Gland Pharma

    Gland Pharma Technicals

    EMA & SMA

    Current Price
    ₹1,792.9
    15.15 (0.85%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹1,726.48
    • 50 Day
    • ₹1,658.37
    • 100 Day
    • ₹1,576.03
    • 200 Day
    • ₹1,566.12
    • 20 Day
    • ₹1,715.10
    • 50 Day
    • ₹1,645.09
    • 100 Day
    • ₹1,583.23
    • 200 Day
    • ₹1,380.76

    Gland Pharma Resistance and Support

    PIVOT
    ₹1,774.42
    Resistance
    First Resistance 1,796.73
    Second Resistance 1,815.72
    Third Resistance 1,838.03
    RSI 63.63
    MFI 77.52
    MACD Single Line 45.59
    MACD 48.55
    Support
    First Resistance 1,755.43
    Second Resistance 1,733.12
    Third Resistance 1,714.13

    Gland Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 321,020 22,503,502 70.1
    Week 322,281 21,567,045 66.92
    1 Month 443,914 23,633,959 53.24
    6 Month 771,106 28,014,265 36.33

    Gland Pharma Result Highlights

    Gland Pharma Synopsis

    NSE-Medical-Generic Drugs

    Gland Pharma is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 3616.53 Cr. and Equity Capital is Rs. 16.47 Cr. for the Year ended 31/03/2023. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276.
    Market Cap 29,280
    Sales 3,606
    Shares in Float 6.92
    No of funds 136
    Yield
    Book Value 3.68
    U/D Vol ratio 1.6
    LTDebt / Equity
    Alpha 0.06
    Beta 0.27

    Gland Pharma

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 57.86%57.86%57.86%57.86%
    Mutual Funds 19.79%20.48%20.25%19.49%
    Insurance Companies 1.79%1.8%2.02%2.59%
    Foreign Portfolio Investors 4.91%2.8%4.33%4.67%
    Financial Institutions/ Banks 0.01%
    Individual Investors 4.52%5.61%4.27%4.02%
    Others 11.12%11.45%11.27%11.37%

    Gland Pharma Management

    Name Designation
    Mr. Yiu Kwan Stanley Lau Chairman & Ind.Director
    Mr. Srinivas Sadu Managing Director & CEO
    Mr. Qiyu Chen Non Executive Director
    Mr. Yao Fang Non Executive Director
    Dr. Jia Ai (Allen) Zhang Non Executive Director
    Mr. Udo Johannes Vetter Independent Director
    Mr. Satyanarayana Murthy Chavali Independent Director
    Mr. Essaji Goolam Vahanvati Independent Director

    Gland Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Gland Pharma Corporate Action

    Date Purpose Remarks
    2023-11-06 Quarterly Results
    2023-08-07 Quarterly Results
    2023-05-18 Audited Results & A.G.M.
    2023-01-23 Quarterly Results
    2022-10-26 Quarterly Results

    Gland Pharma MF Shareholding

    Name Amount(cr)
    ICICI Prudential Balanced Advantage Fund Growth 49,871
    HDFC Mid-Cap Opportunities Fund Growth 47,846
    Nippon India Small Cap Fund - Growth 41,019
    Mirae Asset Large Cap Fund Regular Growth 34,377
    Kotak Emerging Equity Scheme Growth 33,700

    About Gland Pharma

    Gland Pharma is the leading company in creating some of the most beneficial injectable products that have significance in multiple therapeutic segments. In addition, the company is responsible for creating an online portfolio that allows users to buy their products online with a doctor's prescription. Right now, the company is manufacturing its products in seven different locations in India and which produce 750 million units with ease. The four major manufacturing facilities of the company have 22 production lines in order to provide finished formulations along with the Active Pharmaceutical Ingredient (API) Facilities as well. All the products that the company manufactures are delivered in the form of liquid vials, syringes that are pre-filled, ampoules, drops, and even bags as well. 

    In addition to this, the company is also putting a lot of effort into research for manufacturing and creating a delivery system that could hold complex injectables like peptides, suspensions, and long-lasting injectables. Apart from this, Gland Pharma Ltd is also putting its efforts into research and development of synthesizing some of the most complex molecules for the production of their injectables. Lastly, Gland Pharma Ltd is building the market of niche products in the pharmaceutical industry in India and throughout the world. 
     

    Products offered by Gland Pharma Ltd.

    • Anti Malarials
    • Anti-Infectives
    • Anti-Neoplastics
    • Blood Related
    • Cardiac
    • Gastro Intestinal
    • Gynaecological
    • Hormones
    • Neuro / Cns
    • Ophthal / Otologicals
    • Others
    • Pain / Analgesics
    • Respiratory
    • Vitamins / Minerals / Nutrients

     

    Gland Pharma Ltd is listed on 2 exchanges, and these are:

    • National Stock Exchange of India Ltd.
    • The Stock Exchange, Mumbai


    Included in Indices

    • NIFTY 50 - No 
    • NIFTY next 50 - YES
    • NIFTY 100 - YES
    • S&P BSE 200 - YES
    • S&P BSE 250 large midcap index- YES
    • S&P BSE finance- NO

    Other listing information

    • Incorporation date - March 20 1978
    • BSE group - A 
    • BSE Code - 543245
    • NSE - GLANDEQ

    1978
    PVN Raju establishes Gland Pharma to manufacture and market Heparin injection in the domestic market, as well as to provide contract manufacturing services to other pharmaceutical companies.

    1994
    From a private limited company, it becomes a public limited company.

    1996
    Becomes the first company to establish a PFS facility in India.

    2000
    Signs its first Contract Manufacturing agreement for regulated markets

    2007
    Enters the US market with Ketorolac PFS

    2013
    Entered European markets with Tirofiban
    The Visakhapatnam Oncology Formulations Facility has been approved by the USFDA.

    2016
    In 2016, the USFDA granted the first approval for a Penems plant in Hyderabad, as well as a Sterile Injectable plant in Pashamylaram, Hyderabad.
    First USFDA approval for an API plant in VSEZ and another in Pharmacity, Visakhapatnam.

    2017
    Fosun Pharma acquired a majority stake in the company.

    2018
    Enoxaparin injection received US market approval in 2018.
    The first ophthalmic product has been approved for sale in the United States.

    Gland Pharma FAQs

    What is Share Price of Gland Pharma ?

    Gland Pharma share price is ₹1,792 As on 11 December, 2023 | 12:08

    What is the Market Cap of Gland Pharma ?

    The Market Cap of Gland Pharma is ₹29529.4 Cr As on 11 December, 2023 | 12:08

    What is the P/E ratio of Gland Pharma ?

    The P/E ratio of Gland Pharma is 42.3 As on 11 December, 2023 | 12:08

    What is the PB ratio of Gland Pharma ?

    The PB ratio of Gland Pharma is 3.7 As on 11 December, 2023 | 12:08

    Is it a good time to invest in Gland Pharma Limited?

    Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.

    What is the stock price CAGR of Gland Pharma Limited?

    The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.

    Is Gland Pharma Limited debt-free?

    Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

    What is the ROE of Gland Pharma Limited?

    The ROE of Gland Pharma Limited is 16% is which good.

    Who is the Managing Director of Gland Pharma Limited?

    Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.

    How to buy shares of Gland Pharma Ltd online?

    The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

    What are some of the competitors of Gland Pharma Ltd?

    Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd. 

    • Cipla 
    • Sun Pharma 
    • Pfizer 
    • Lupin
    • Eris Life 
    • Aarti Drugs 
    • Hester Bio
    • RPG Life 
    • Bafna Pharma 
    • Jb Chemicals 

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.